ImmunoPET Imaging With 89Zr-MPDL3280A in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Bladder Cancer or Triple-negative Breast Cancer Prior to MPDL3280A Treatment
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Atezolizumab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Non-small cell lung cancer
- Focus Pharmacokinetics
- 09 Nov 2017 Planned End Date changed from 1 Jul 2017 to 1 Feb 2018.
- 09 Nov 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Feb 2018.
- 10 Jun 2017 Biomarkers information updated